Parima Daroui
Associate Professor, Radiation Oncology
School of Medicine
School of Medicine
M.D., UMDNJ-Robert Wood Johnson Medical School
Ph.D., Rutgers University-UMDNJ Joint Molecular Biosciences Program, Molecular Cancer Pharmacology
M.S., Azad University, Tehran, Organic Chemistry
B.S., Azad University, Tehran, Applied Chemistry
Ph.D., Rutgers University-UMDNJ Joint Molecular Biosciences Program, Molecular Cancer Pharmacology
M.S., Azad University, Tehran, Organic Chemistry
B.S., Azad University, Tehran, Applied Chemistry
University of California, Irvine
Department of Radiation Oncology
101 The City Drive S., B-23, Rt 26
Mail Code: 2690
Orange, CA 92868
Department of Radiation Oncology
101 The City Drive S., B-23, Rt 26
Mail Code: 2690
Orange, CA 92868
Research Interests
Breast Cancer, Head and Neck Cancer
Academic Distinctions
Orange County Medical Association/Orange Coast Magazine Physician of Excellence 2018
Outstanding Patient Satisfaction and Communication Award
Member of ASTRO Science and Education Research Council
Member of ASTRO Radiation and Cancer Biology Committee Research Council
Gallo Award for Outstanding Cancer Research, The Cancer Institute of New Jersey
Young Investigator Award, Department of Pharmacology, UMDNJ
Outstanding Patient Satisfaction and Communication Award
Member of ASTRO Science and Education Research Council
Member of ASTRO Radiation and Cancer Biology Committee Research Council
Gallo Award for Outstanding Cancer Research, The Cancer Institute of New Jersey
Young Investigator Award, Department of Pharmacology, UMDNJ
Publications
1) K. Sindhu, W. Armstrong, A. Hasso, T. Farzaneh, Parima Daroui “Recurrent squamous cell carcinoma involving cranial nerves in a patient with left glottic carcinoma treated with definitive radiation therapy: a case report” Practical Radiation Oncology , Mar – Apr; 7(2):100-102.
2) M. Connor, R. Wei, S. Yu, V, Sehgal, S. Klempner, Parima Daroui “Radiation Dermatitis Caused by a Bolus Effect from an Abdominal Compression Device” Medical Dosimetry 2016;41(3):221-4.
3) Yu S, Lawrenson L, Wei R, Sehgal V, Hanna N, Kuo J, Parima Daroui, Ramsinghani N, Al-Ghazi M. “The dosimetric impact of image guided radiation therapy by intratumoral fiducial markers.” Pract Radiat Oncol. 2016 Jul-Aug;6(4):276-83
4) Parima Daroui, S. Jabbour et al. “American College of Radiology (ACR) Appropriateness Criteria-Resectable Stomach Cancer, Oncology, 2015 Aug;29(8):595-602
5) J. Mayadev, J. Einck; S. Elson, H. Rugo, S. Hwang, R. Bold, Parima Daroui, S. McCloskey, C. Yashar, D. Kim, B. Fowble “Practice Patterns in the Delivery of Post Mastectomy Radiation Therapy among the University of California Athena Breast Health Network”; Clinical Breast Cancer, 2015 Feb;15(1):43-7
6) S. Goyal, Parima Daroui, A. Khan, T. Kearney, M. Azu, S. Chen, D. Pierce , B.G. Haffty “Acute Loco-Regional Toxicity of a Novel Fractionation Scheme for Accelerated Partial Breast Irradiation (APBI) Using 3-D Conformal Radiotherapy (3D-CRT)" Cancer Medicine, Dec 2013; Vol 2(6): pp 964-971
7) Parima Daroui, B. Haffty “The Role of Radiation Therapy in DCIS”, Chapter 2, Radiation Medicine Rounds Series: Breast Cancer; Volume 3 Issue 1, Editors: Alphonse Taghian, Michele Halyard, Charles Thomas Jr., April 2012, Demos Medical Publishing
8) Parima Daroui, M. Gabel, B.G. Haffty, A. Khan, S. Goyal “Utilization of Breast Conserving Therapy in Stage 0, I, II Breast Cancer Patients in New Jersey: An American College of Surgeons National Cancer Data Base (NCDB) Analysis” American Journal of Clinical Oncology, Feb 15 2011
9) S. Jabbour, Parima Daroui, D. Moore, E. Licitra, M. Gabel, J. Aisner, “A Novel Paradigm in the Treatment of Oligometastatic Non-Small Cell Lung Cancer” . Journal of Thoracic Disease, Vol 3, No 1 , 2011
10) Parima Daroui, B.G. Haffty “Commentary on High Chemokine receptor CXCR4 Level in Triple Negative Breast Cancer Specimens Predicts Poor Clinical Outcome”, Chu, Q.D et al., Journal of Surgical Research, 2010; 159:689–95. Accepted for Publication in Breast Diseases: A Year Book Quarterly
11) Parima Daroui, Desai SD, Li TK, Liu AA, Liu LF. “Hydrogen Peroxide Induces Topoisomerase I-mediated DNA Damage and Cell Death.” Journal of Biological Chemistry, Apr 9 2004; Vol. 279(15): pp 14587-94.
12) Li TK, Houghton PJ, Desai SD, Parima Daroui, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, Liu LF. “Characterization of ARC-111 as a Novel Topoisomerase I-Targeting Anticancer Drug.” Cancer Research, Dec 1 2003; Vol. 63(23): pp 8400-7.
2) M. Connor, R. Wei, S. Yu, V, Sehgal, S. Klempner, Parima Daroui “Radiation Dermatitis Caused by a Bolus Effect from an Abdominal Compression Device” Medical Dosimetry 2016;41(3):221-4.
3) Yu S, Lawrenson L, Wei R, Sehgal V, Hanna N, Kuo J, Parima Daroui, Ramsinghani N, Al-Ghazi M. “The dosimetric impact of image guided radiation therapy by intratumoral fiducial markers.” Pract Radiat Oncol. 2016 Jul-Aug;6(4):276-83
4) Parima Daroui, S. Jabbour et al. “American College of Radiology (ACR) Appropriateness Criteria-Resectable Stomach Cancer, Oncology, 2015 Aug;29(8):595-602
5) J. Mayadev, J. Einck; S. Elson, H. Rugo, S. Hwang, R. Bold, Parima Daroui, S. McCloskey, C. Yashar, D. Kim, B. Fowble “Practice Patterns in the Delivery of Post Mastectomy Radiation Therapy among the University of California Athena Breast Health Network”; Clinical Breast Cancer, 2015 Feb;15(1):43-7
6) S. Goyal, Parima Daroui, A. Khan, T. Kearney, M. Azu, S. Chen, D. Pierce , B.G. Haffty “Acute Loco-Regional Toxicity of a Novel Fractionation Scheme for Accelerated Partial Breast Irradiation (APBI) Using 3-D Conformal Radiotherapy (3D-CRT)" Cancer Medicine, Dec 2013; Vol 2(6): pp 964-971
7) Parima Daroui, B. Haffty “The Role of Radiation Therapy in DCIS”, Chapter 2, Radiation Medicine Rounds Series: Breast Cancer; Volume 3 Issue 1, Editors: Alphonse Taghian, Michele Halyard, Charles Thomas Jr., April 2012, Demos Medical Publishing
8) Parima Daroui, M. Gabel, B.G. Haffty, A. Khan, S. Goyal “Utilization of Breast Conserving Therapy in Stage 0, I, II Breast Cancer Patients in New Jersey: An American College of Surgeons National Cancer Data Base (NCDB) Analysis” American Journal of Clinical Oncology, Feb 15 2011
9) S. Jabbour, Parima Daroui, D. Moore, E. Licitra, M. Gabel, J. Aisner, “A Novel Paradigm in the Treatment of Oligometastatic Non-Small Cell Lung Cancer” . Journal of Thoracic Disease, Vol 3, No 1 , 2011
10) Parima Daroui, B.G. Haffty “Commentary on High Chemokine receptor CXCR4 Level in Triple Negative Breast Cancer Specimens Predicts Poor Clinical Outcome”, Chu, Q.D et al., Journal of Surgical Research, 2010; 159:689–95. Accepted for Publication in Breast Diseases: A Year Book Quarterly
11) Parima Daroui, Desai SD, Li TK, Liu AA, Liu LF. “Hydrogen Peroxide Induces Topoisomerase I-mediated DNA Damage and Cell Death.” Journal of Biological Chemistry, Apr 9 2004; Vol. 279(15): pp 14587-94.
12) Li TK, Houghton PJ, Desai SD, Parima Daroui, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, Liu LF. “Characterization of ARC-111 as a Novel Topoisomerase I-Targeting Anticancer Drug.” Cancer Research, Dec 1 2003; Vol. 63(23): pp 8400-7.
Professional Societies
American Society of Radiation Oncology (ASTRO)
Radiological Society of North America (RSNA)
American Brachytherapy Society (ABS)
American Society of Clinical Oncology (ASCO)
American Association for Cancer Research (AACR)
American Roentgen Ray Society (ARRS)
American College of Radiation Oncologists (ACRO)
American Radium Society (ARS)
Link to this profile
https://faculty.uci.edu/profile/?facultyId=5870
https://faculty.uci.edu/profile/?facultyId=5870
Last updated
02/09/2018
02/09/2018